The BEST place to inject your GLP-1

Index of Contents →

Share this article

Watch this on YouTube.

Where is the best place to inject your GLP-1 medication? Spend just five minutes on TikTok, and you’ll find people who are absolutely convinced they have cracked the code. “Inject here and you’ll lose more weight.” “Inject there and you’ll have fewer side effects.” These claims can sound convincing, especially when people are sharing their own personal experiences.

Then, on the other hand, many doctors will tell you that it doesn’t really matter. As long as you use one of the approved GLP-1 injection sites, you should be fine.

So, who is right?

Let’s put aside the TikTok advice, personal anecdotes, and even general recommendations for a moment. What does the actual clinical evidence say? If you inject a GLP-1 medication into your abdomen, thigh, or upper arm, does the injection site really make a difference?

GLP-1 Injection Site Absorption Differences

Let’s start with drug absorption. In simple terms, absorption refers to how much of the medication gets into your body and becomes available to do its job.

GLP-1 medications are designed to be injected subcutaneously, which means into the layer of fat just beneath your skin. These are not intramuscular injections, so you are not trying to inject the medication into muscle. Instead, the goal is to inject it into fatty tissue.

And yes, where you inject a medication under the skin can sometimes affect how it is absorbed.

Research on various medications has shown that different areas of the body can have differences in blood flow, fat distribution, connective tissue, and tissue thickness. All of these factors can potentially influence how quickly a medication is absorbed and how much of it reaches your bloodstream.

However, there is an important catch: you cannot assume that every medication behaves the same way. What is true for one subcutaneous medication may not necessarily be true for another.

So, what does the research specifically show for GLP-1 medications?

Liraglutide Injection Sites

Let’s start with liraglutide, an older GLP-1 medication sold under the brand name Saxenda.

Researchers compared injections into the abdomen, thigh, and upper arm. Overall, liraglutide absorption was fairly similar across all three injection sites. However, there was a noticeable trend: the abdomen produced the highest drug exposure, while the thigh produced the lowest.

The difference was not enormous, but it was measurable.

Semaglutide Injection Sites

Next is semaglutide, the active medication in Ozempic and Wegovy.

Research comparing different injection sites found that semaglutide had approximately 12% lower bioavailability when injected into the thigh compared with the abdomen. In other words, slightly less of the medication reached the bloodstream when it was injected into the thigh.

Once again, the abdomen appeared to have a small advantage over the thigh when it came to overall drug exposure.

Tirzepatide Injection Sites

A similar pattern has also been seen with tirzepatide, the medication used in Mounjaro and Zepbound.

Researchers compared injections into the abdomen, thigh, and upper arm. Again, the abdomen produced the highest drug concentrations, while the thigh produced the lowest.

At this point, you might be thinking, “Well, there you have it. The stomach is clearly the best place to inject a GLP-1.”

Not so fast.

The research does suggest that the abdomen and upper arm may generally produce slightly greater drug exposure than the thigh. However, these differences are relatively small. More importantly, having slightly more medication in your bloodstream does not automatically mean you will lose more weight, have better blood sugar control, or experience fewer side effects.

Do Different GLP-1 Injection Sites Affect Weight Loss?

This brings us to the million-dollar question: do these small differences in absorption actually matter when it comes to weight loss, blood sugar levels, or GLP-1 side effects?

Based on the available research, probably not.

Take semaglutide as an example. Researchers have looked at injection sites alongside actual clinical outcomes and have not found meaningful differences in weight loss or side effects between the approved injection areas.

In other words, semaglutide may be absorbed slightly differently depending on whether you inject it into your abdomen, thigh, or upper arm. However, those small differences do not appear to translate into dramatically different results.

This is an important point because your GLP-1 injection site is only one very small piece of a much larger puzzle.

Factors such as your starting body weight, blood sugar levels, age, body composition, diet, and individual response to the medication are likely to have a much greater impact on your results than whether you inject your GLP-1 medication into your stomach or thigh.

The Best Injection Site for GLP-1 Medications

So, what is the bottom line?

If we look strictly at drug absorption, the abdomen and upper arm generally appear to produce similar levels of drug exposure, while the thigh may sometimes produce slightly lower levels. However, these differences are small.

There is simply no good evidence that injecting your GLP-1 medication into your abdomen will magically produce more weight loss, better blood sugar control, or fewer side effects compared with injecting into your thigh or upper arm.

So, if someone on TikTok tells you that you *have* to inject into your stomach because that is where you will get the best results, don’t confuse their personal experience with clinical evidence.

They may genuinely feel that the medication worked better for them when injected in a particular location. But that does not mean the same thing will happen for you.

Your body weight, fat distribution, blood sugar levels, metabolism, and individual response to the medication can all influence how your body responds to a GLP-1 injection. Because these factors vary so much from person to person, trying to copy someone else’s injection strategy can be a bit of a fool’s errand.

There is, however, one thing I would not ignore: rotating your injection sites.

If you become convinced that one location is the “best” and repeatedly inject into the exact same area week after week, you may irritate the tissue. Over time, repeated injections in the same spot can contribute to problems such as lumps, thickened tissue, or scar tissue.

Instead of obsessing over finding one magical injection spot, I recommend a much simpler approach. Use the approved GLP-1 injection areas, rotate between different locations, and choose sites that work well for you in terms of comfort and convenience.

When we look at the clinical evidence, there does not appear to be one universally superior GLP-1 injection site.

The abdomen may provide slightly greater drug exposure. The thigh may provide slightly less. But when it comes to the outcomes most people actually care about—weight loss, blood sugar control, and side effects—the differences appear to be negligible.

So, forget the idea of a magic injection spot.

As long as you are using an approved, safe, and comfortable injection site and rotating your injection locations regularly, the best place to inject your GLP-1 medication is simply the location that works best for you.

Learn more about

What Forms of Semaglutide are Available?

Comparing other GLP-1 Agonists for Weight Loss

Other weight loss medications

Citations

Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Diabetes Ther. 2018 Aug;9(4):1533-1547. doi: 10.1007/s13300-018-0458-5. Epub 2018 Jun 15. PMID: 29907893; PMCID: PMC6064581.

Eli Lilly and Company. (2023, May 6). Effect of injection site on the relative bioavailability of a single dose of tirzepatide in subjects with low and high body mass indices (ClinicalTrials.gov Identifier NCT04050670). ClinicalTrials.gov.

Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol. 2011 Jun;51(6):951-5. doi: 10.1177/0091270010374474. Epub 2010 Jul 29. PMID: 20671294.

Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH. Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. Diabetes Ther. 2019 Apr;10(2):649-662. doi: 10.1007/s13300-019-0581-y. Epub 2019 Feb 20. PMID: 30788808; PMCID: PMC6437231.

Zou P, Wang F, Wang J, Lu Y, Tran D, Seo SK. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. J Control Release. 2021 Aug 10;336:310-321. doi: 10.1016/j.jconrel.2021.06.038. Epub 2021 Jun 26. PMID: 34186147.